Danish Biotech Breye Therapeutics Secures $73M to Revolutionize Eye Disease Treatment

·
Listen to this article~3 min

Breye Therapeutics raises $73M to develop oral treatments for retinal diseases, potentially replacing painful eye injections and transforming care for millions.

### A Massive Vote of Confidence Breye Therapeutics, a Danish biopharmaceutical company you've probably never heard of, just closed an oversubscribed $73 million Series A round. That's not pocket change. It's a clear signal that investors believe in their vision: oral treatments for retinal diseases that could replace those dreaded eye injections. The round was co-led by Mission BioCapital and Novo Holdings, with Sound Bioventures and a handful of new investors joining in. Robert Blazej from Mission BioCapital and Lukas Ljungström also joined the board. ### Why This Matters Diabetic retinopathy affects about 130 million people worldwide. It's a leading cause of vision loss among working-age adults. Current treatments? They involve injecting drugs directly into the eye. Not exactly a walk in the park. Many patients skip appointments because of the discomfort. Breye's lead candidate, danegaptide, is an oral pill. It's designed to stabilize retinal blood vessels and prevent leakage caused by high blood sugar. In a Phase 1b trial, it was well tolerated and showed early signs of reducing vascular leakage. ### The Road Ahead With this funding, Breye plans to push danegaptide into the next phase of clinical development. The company is also exploring treatments for age-related macular degeneration and glaucoma. If successful, it could transform how we treat eye diseases. No more needles. Just a pill. As CEO Ulrik Mouritzen put it: "This financing enables us to advance danegaptide to the next stage of clinical development – bringing a much-needed patient-friendly treatment option closer to those living with this debilitating eye disease." ### What to Watch - **Clinical trial results**: Phase 2 data will be crucial. - **Regulatory path**: The FDA and EMA will scrutinize the data. - **Competition**: Other companies are also working on oral therapies for retinal diseases. Breye's journey is one to watch. It's not every day a Danish startup raises this kind of cash to take on a global health problem. But if they succeed, it could mean a world where treating diabetic retinopathy doesn't require a trip to the ophthalmologist every few weeks.

📌 Worth Reading Next